2018 Speaker Bios
Mark Adams has had two very different careers in his life, and has embarked on a third. The first was in law enforcement, where he spent 21 years as a member of the Philadelphia Police Dept., retiring as a Captain. His second career was at Merck & Co., where he spent 14 years in the Compliance Dept., retiring as an Executive Director. Currently, he is the VP of Audits at G&M Health, LLC. He has a Masters degree from St Joseph’s University in Public Safety. In his 17-year tenure with the Alliance, he has been President, VP, Treasurer and Operations Director. He feels the members all share a sense of purpose, that of compliance. He brings value to the group through his varied life experiences and hopes that this experience helps solve compliance-related issues for members. Mark has been married for 40 years, with 2 grown children, a grandson and a granddaughter. In his spare time, he enjoys the Jersey shore, and daydreaming of life on the Senior PGA Tour.
James A. Arnold currently serves as Chief of the Liaison Section, Diversion Control Division, Drug Enforcement Administration (DEA) at DEA Headquarters in Washington, DC. Jim has also served as the Chief of the Policy Unit and the Chief of the Regulatory Unit at DEA Headquarters, as well as in various other investigative and supervisory positions at the DEA New Jersey Field Division, Newark, New Jersey. His efforts in the New Jersey Field Division focused on administrative, civil, and criminal investigations of DEA registrants and other individuals and organizations who were engaged in violations of the Controlled Substances Act and/or with other illegal activities with legitimate, and illegal, controlled substances and listed chemicals. With over 30 years of experience with the DEA Jim has spoken nationwide on numerous regulatory subjects; has coordinated and spearheaded investigations on various regulatory issues of nationwide importance for DEA and the Department of Justice; was intimately involved with various investigations and prosecutions of DEA registrants at the height of the opioid prescription drug problem in south Florida in 2011 and 2012; and has been an Instructor at the DEA Justice Training Center in Quantico, Virginia, for Intelligence Research Specialists, Special Agents of Tactical Diversion Squads, and new Basic Diversion Investigator Classes since July of 1999. Jim is a proud graduate of West Chester State University and Drew University, where he received a Master’s Degree. Jim has been the recipient of numerous awards and commendations throughout his DEA career in recognition of many successful investigations and prosecutions, and for his leadership, performance and commitment to public service.
Isha Arora is currently Chicago based Compliance Manager at Horizon Pharma. A native to Houston, TX, Isha proceeded to Northeastern University in Boston where she received a BA in Finance and Health Sciences. After working at Big Pharma in Cambridge, Massachusetts, she moved over to Horizon Pharma in Chicago where the entrepreneurial attitude allows her to be creative with her role. Isha is passionate about learning the ever changing compliance regulations, specifically the complexities around transparency aggregate spend reporting, and is intrigued with the development of big data to support compliance. She enjoys working in the Biopharma industry as it allows her to play her strengths in business while also being able to see a direct impact on the lives of patients. In her spare time she likes to travel and stay active.
Brian Bauer is an industry recognized expert in the area of PDMA compliance, sample accountability applications and industry sampling solutions trends, with over 25 years of experience in the pharmaceutical arena. Brian joined Priority Solutions International in 2007 and was responsible initially for building a “best in class” Direct to Practitioner platform at the company along with other turnkey program support mechanisms. He is the architect of many of the existing and successful sample send programs that support top tier pharmaceutical manufacturers today. Brian has played a leadership role on numerous PDMA assessment and audit teams, and has directed organizational redesign and implementation initiatives based on the output of the assessment/audit activities. In addition to his background in compliance, Brian’s expertise extends to Patient Assistance Programs and Alternative Sampling Channels. Brian has maintained a finger on the pulse of the pharmaceutical industry and the changes within the current sampling arena, and how companies are addressing and adapting to this new business environment.
Lisa A. Butler is the Associate Director of DEA/PDMA Compliance for Novartis Pharmaceutical Corporation. She has held various roles within the pharmaceutical industry for the last 27 years and has worked within her current area of responsibility for the last seventeen. Lisa’s areas of expertise include DEA Controlled Substance compliance, PDMA Sample Compliance and State and Federal commercial distribution licensing for pharmaceutical products. She holds a B.S. in Business Administration from Centenary College in NJ. Lisa has been an Alliance Board Member since 2009 and is the current Sharing Alliance President. Lisa has been married to her best friend for 20+ years and has two daughters, two sons and two amazing grandchildren.
Robert Celeste has over 30 years of experience in the chemical, financial, pharmaceutical, medical device and retail industries with a focus on business process re-engineering, information management, standards development and usage. For the past 13 years, Bob was Senior Director, Healthcare with GS1, EPCglobal and GS1 US where he concentrated on working with regulators (FDA, DEA, California, Florida and Nevada Boards of Pharmacy) on the proper use of Master Data Management and track and trace information and practice. In this capacity, he provided numerous presentations and talks on the subjects of drug traceability, in particular on the 2013 Drug Supply Chain Security Act (DSCSA, Title II of the DQSA) and product Unique Device Identification regulation (UDI).
Alex Celius is Senior Manager, Compliance for Pacira Pharmaceuticals, Inc., with 9 years of experience in the Life Sciences industry. He has extensive experience in the pharmaceutical industry in regulatory and compliance matters, including field-based auditing and monitoring, investigations, KOL training, federal and state transparency reporting, advertising and promotional activities, and interactions with healthcare practitioners.
TJ Christl attended college at the University of Miami (Coral Gables, FL). He double majored in biology and marine science, and competed all 4 years as a walk on member of the UM Springboard/Platform Diving Team, earning Academic All-Big East honors. He graduated in 1995 with General Honors and as a member of the marine and atmospheric science honor society ppp (Rho Rho Rho). Following graduation TJ attended the Medical University of South Carolina, where he earned his MS in Biomedical Sciences studying ability of the Eastern oyster (Crassostrea virginia) to resist the toxic effects of pesticides commonly found in coastal waters. He joined the FDA in CDER’s Office of Counter-Terrorism and Pediatrics, Division of Counter-Terrorism as a project manager in 2003. As a project manager he was responsible for coordinating activities related to medical countermeasures against Bacillus anthracis (anthrax) and Yersinia pestis (plague) for several years before transitioning to focus on the newly emerging emergency response and coordination program for FDA’s Center for Drug Evaluation and Research. For the duration of his work in OCTEC he continued to lead the development of the emergency response and coordination program within CDER through participation in numerous agency and national level exercises, as well as responding to events such as heparin contamination in 2008, the 2009 H1N1 pandemic, 2010 Haiti earthquake, and 2011Japan earthquake and tsunami. In August, 2011 CDR Christl joined CDER’s Office of Compliance as the Deputy Director of the Office of Drug Security, Integrity and Response (ODSIR), and was promoted to Director of the office in January, 2012. ODSIR is responsible for programs ensuring the safety and security of the pharmaceutical supply chain including imports, exports, recalls, shortages; as well as preventing, detecting and responding to suspect or illegitimate products in the supply chain (such as counterfeits or stolen products) and coordination of incident/emergency response activities for the Office of Compliance.
Steve Conn has worked in the pharmaceutical sales sample distribution industry for just over 26 years. He is currently Vice President of Business Development and Client Services at Genesis Logistics. Steve heads up the Genesis Logistics PDMA division, which offers logistical services to pharmaceutical clients. In his current role Steve works closely with Sample Accountability, Compliance and Logistics in the coordination, planning and execution of regulated deliveries of sales samples to field representative in accordance to the PDMA guidelines. Steve has a B.S in Finance from Monmouth Universe and currently lives in Titusville, NJ with his beautiful 9-year-old daughter. This is Steve’s second year as a member of the Alliance Board.
Don De Smet is Manager of Sample Operations – Cold Chain for Sanofi and is responsible for cold chain equipment deployment, cold chain field monitoring and field compliance to cold chain requirements. Previously Don was Manager of Accountability for Bayer Healthcare for 17 years and was responsible for all aspects of PDMA compliance, Sample Vendor Partner Management, and Bayer’s Sample Send program. Don has served on the Sharing Alliance board for 14 years, and has held the positions of both President and Vice President. Prior to Bayer, Don spent 25 years in various senior logistics and warehouse operations positions for both Pharma and consumer goods organizations. Don also owned a contract packaging concern for 5 years. Don holds a BA in Materials and Logistics Management from Michigan State University.
Danielle Dowling has over 17 years of experience with Sample Accountability/PDMA and Fleet. She is dedicated to driving business performance through managing the Sample and Fleet Programs for Mallinckrodt in Bedminster, NJ. Danielle is recognized for guiding the sales teams and stakeholders with great focus on compliance, strategy, and continuous process optimization. She has most recently achieved awards on her collaborative efforts from leadership, peers, and on making an impact. Danielle holds a B.S. degree in Business Administration with a concentration in Management from College of St. Elizabeth in Convent Station, NJ. Danielle enjoys spending time with her two teenage daughters and strives to make every day count.
Phillip Eng is a Sr. Digital Advisor with three decades of new product innovation and business technology strategy expertise. Using design thinking and systems thinking to drive business outcomes at an ecosystem scale, he has driven the digital transformation of aerospace and defense systems, telecommunications, real-time information media, global financial markets, life sciences and healthcare industries. Previously at JPMorgan, he led the Agile Business Transformation Program for Worldwide Securities, Product Manager for the Compute BackBone for Firmwide Risk. At Bloomberg, he led Equity Derivatives Product R&D delivering real-time and historical analytics to the global markets. Lead Network and Application Technology Strategy at Reuters Ventures leading to the JV Radianz – a global telco arm of BT. Prior product design and manufacturing includes avionics and embedded systems. He has a BSEE from the Polytechnic University / NYU Tandon School of Engineering. He started with Biomedical Engineering a long time ago.
Mark Faloon is currently Manager, Compliance Monitoring & Analytics with Takeda Pharmaceuticals, U.S.A. Mark has held several roles in the Compliance function since joining Takeda in 2011. In his current role, Mark is responsible for leading the US BU commercial monitoring and analytics program. He also contributes to policy development, business engagement, training activities, and Takeda’s transparency reporting program. Recently, Mark has served as program management lead for Takeda’s Global Monitoring Program, helping to create a scalable, flexible, and globally consistent monitoring approach. Mark earned a J.D. from the University of Michigan Law School and a B.A. from Indiana University.
Teresa Farmer is the Associate Director of Sales Operations for Otsuka America Pharmaceutical, Inc. Teresa has been in the Pharmaceutical Industry for over 25 years working in various Functional areas such as Finance, Sales and Sales Operations. In her current role, Teresa oversees all Otsuka Rep Hand Carry and Direct to Practitioner Sampling programs. Teresa has a Bachelor’s Degree in Accounting and a Master’s Degree in Fraud and Forensic Accounting from Rider University.
Jill Feldman is the Head of Quality and Compliance at Medac Pharma, Inc, a pharmaceutical company with a focus on advancing and commercializing therapies for autoimmune diseases and cancer. For the last 20 years, she has worked for both small and large pharmaceutical companies in multiple quality and compliance roles. Her expertise is in determining root cause for issues of varying complexity and developing solutions that are both cost-effective and compliant. Jill holds a B.S. in Chemical Engineering from Purdue University and has been a member of the Sharing Alliance since 2015.
Virginia Fitt is Senior Counsel with GlaxoSmithKline, focusing on pharmaceutical sales and marketing law, transfers of value, sampling, and health policy. Prior to joining GSK, Virginia worked with the international law firm of Gibson, Dunn & Crutcher LLP, in transnational disputes, white collar defense and investigations, and complex litigation. She graduated from Duke University School of Law cum laude and received her B.A. from the University of North Carolina at Chapel Hill.
Paul Hamby holds the position of Group Director, US Compliance (formerly BuzzeoPDMA) with IQVIA. Mr. Hamby has been with the organization since July 1997 and directs all day to day operational activities and functions for the 100+ employee US Compliance business unit. In this capacity, Mr. Hamby is responsible for delivery of superior customer satisfaction to a wide range of US Compliance customers including pharmaceutical manufacturers, drug distributors, medical device, animal health, pharmacies and hospitals. Mr. Hamby leads a diverse portfolio of support services that assist Healthcare companies strengthen and enhance their federal and state regulatory compliance efforts including sample management/accountability, computer systems validation and Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), and state regulatory compliance. Mr. Hamby is a Subject Matter Expert in the Prescription Drug Marketing Act (PDMA), FDA’s Title 21 CFR Parts 11 and 203, and the DEA’s Suspicious Order Monitoring (SOM) requirements. Prior to his time in the Life Sciences sector, Mr. Hamby was employed for seven years as a civilian for the Naval Air Warfare Center where he led software testing and software process improvement efforts for various Navy and Marine helicopters, including the Presidential Helicopter program. Mr. Hamby earned a BS in Computer Engineering from Clemson University.
Steve Haynes is the Alliance Director of Operations. Steve brings over 40 years of experience to the Alliance board. He retired from FDA's Office of Criminal Investigations in 1999 as Special Agent in Charge of their Investigative Operations Division. In the years since, he has worked closely with pharmaceutical clients and our Sharing Alliance on a wide range of corporate compliance matters, including investigations, regulatory compliance, and litigation support services, to include federal court testimony as an expert witness on PDMA law. Steve's experience also includes three years as an instructor at a federal law enforcement training academy, where he taught "Interviews and Interrogations" and other investigative courses.
Mark Jara is Principal and Co-Founder of RxS LLC located in Manalapan, NJ. RxS is a Multi-Channel Sample Management company focused on delivering PDMA solutions and services to Life Science, Pharmaceutical and Biotechs large and small. He has held numerous technology leadership positions at various organizations building enterprise solutions, supporting PDMA Compliance for over 16 years. Prior to Pharma, Mark held similar leadership and technical development lead roles in Telecommunications, IT Consulting, Financial Markets and Media Research. He holds an M.S. Management from Stevens Institute and a B.A. Information Management from Rutgers Newark/ NJIT. He is also an active speaker on topics related to Multi-Channel Sampling Programs, Compliance and Technology’s Impact to Pharma. He resides in Sayreville, NJ with his wife Renata and twin boys Gregory and Dylan.
Kevin Johnston joined Synergy Pharmaceuticals in 2016 to design and implement their commercial and marketing operations functions in support the launch of their first commercial product. Prior to joining Synergy he spent 15 years in the pharma industry in varying commercial operations roles at Shire & Endo Pharmaceuticals and consulting with Highpoint Solutions in their Master Data Management practice.
Tom Lederer has been at Merck & Company, Inc since October of 2004. Tom was first hired as a logistics manager and was an on-site contractor responsible for the returns of samples. He was hired as a Merck employee initially to do audits of representatives. Tom was promoted and has responsibility for various processes including Physician Audit Letters (PALs), access to health care facilities, and a segment of HCP validation. Tom was a 25 year member of the Philadelphia Police Department and served in various ranks and bureaus. He was also an adjunct professor at local Philadelphia universities. Tom holds a BS in Accounting and a MS in Business – Public Safety. Both degrees are from the Haub School of Business at Saint Joseph University in Philadelphia.
Alan G. Minsk is a Partner and Chair of the Food & Drug Practice Team of Arnall Golden Gregory LLP. Alan advises pharmaceutical, medical device and food companies on all legal and regulatory matters relating to the U.S. Food and Drug Administration, and certain matters concerning the U.S. Department of Agriculture, the Federal Trade Commission, the Drug Enforcement Administration, the Bureau of Alcohol, Tobacco and Firearms, and the Consumer Product Safety Commission. He counsels clients and has spoken and written on a wide variety of FDA-related issues, including regulatory strategies and life cycle management, combination products, FDA enforcement, FDA inspections, corporate compliance, market exclusivity, product promotion and advertising, product liability, clinical trials and imports and exports. He serves on several Editorial Advisory Boards and the Sharing Alliance as the General Counsel. He is a graduate of Brandeis University and Georgetown University Law Center.
Lori Peters serves as Senior Vice President, Commercial Operations at QPharma. A subject matter expert on life sciences product launches and commercialization, she oversees client implementations and day-to-day operations within the company’s Commercial Services group, with responsibility for solutions that include sample management, fulfillment, product launch services, Key Opinion Leader (KOL) engagement, and training. She holds a business degree from Berkeley College.
Lora Posey graduated from Lehigh University and worked briefly in the financial sector. Lora started in the pharmaceutical industry in 1999 as a contract representative with Bristol-Myers Squibb. She joined Mission in 2001 where she was a Territory Sales Manager for 10 years. She then moved to Alamo Pharma Services as a Project Manager (2011) and then National Manager, Sales Training and Development (2013). She has been a District Manager in the Women’s Health division at Mission Pharmacal since 2016.
Kelly Pryslak has 14 years of PDMA Sample Compliance experience. She is currently the Sr. Manager of Sample Compliance & SAFE Fleet at Janssen Pharmaceuticals, Inc. based in Titusville, NJ. In this capacity, Kelly provides leadership in maintaining the highest quality compliance, providing guidance to supported sales forces and business partners as well as ensuring internal policies and procedures meet Federal PDMA, State, Corporate and CIA requirements. Kelly is a current Member of the Sharing Alliance Board.
Mary E. Riordan is a Senior Counsel in the Office Inspector General (OIG) for the U.S. Department of Health and Human Services. Mary specializes in cases and issues involving pharmaceutical and device manufacturers. She primarily handles cases brought under the federal False Claims Act involving alleged fraud against Medicare and Medicaid by drug and device manufacturers. She has represented the OIG in the negotiation of numerous settlements and Corporate Integrity Agreements (CIAs). Mary also monitors several CIAs with pharmaceutical manufacturers. In addition to her casework, she was a co-organizer of the OIG’s February 2012 Pharmaceutical Compliance Roundtable and a co-author of the OIG's 2003 Compliance Program Guidance for Pharmaceutical Manufacturers.
Deb Segura is the Executive Director of the Sharing Alliance, and has over 25 years of experience in the pharmaceutical industry. She has dedicated herself to providing valuable compliance information to Alliance members and industry. The Sharing Alliance is a not for profit organization founded in 1989 with a mission to improve the pharmaceutical industry’s understanding of the Prescription Drug Marketing Act (PDMA) and related sample compliance regulations. Prior to taking the position of Executive Director, Deb’s career included various management positions at Kos Pharmaceutical (now Abbott), Novo Nordisk, and Bristol Myers Squibb. Her primary focus was sample compliance, education and training and sample investigations.
Kevin Sharp has more than 20 years of experience in the pharmaceutical/biotech industry, working primarily in the Sales & Marketing Operations space. His experience ranges from Sales Analysis, Sales Force Automation (SFA), Global Data Management, Patient Assistance Programs (Copay, Coupons, and Starters), Sample Operations and Aggregate Spend for industry leaders Wyeth Pharmaceuticals and Genentech. During his time with these companies, he successfully built and led a number of teams and mentored many colleagues. Kevin also has experience on the 3rd party side, providing such services as the implementation of Business Intelligence, Incentive Compensation and SFA systems as well as Industry Benchmarking and Commercial Compliance consulting services with companies like HighPoint Solutions, TGaS Advisors and G&M Health. Kevin is a proud US Army veteran. He served his county in combat with the U.S. Army, 10th Mountain, Light Infantry in Somalia and Haiti.
Debbie Tay has over twenty years of broad sales operations experience including Sample Compliance, Sales Force Automation, Field Reporting, Fleet, HR/Benefits, Recruiting and Incentive Compensation. She is currently the Senior Manager Sales Operations for Vertical/Osmotica Pharmaceuticals. She is a results producing manager and team member who consistently demonstrates strong leadership in improving systems and processes to meet the business acumen, with in depth experience of more than 15 years of innovative successful sales operations and HR productivity development of intuitive compliant processes. She has led advances in technology and field enablement for a variety of Specialty Pharmaceutical, Hospital and Managed Markets teams. In addition to incentive compensation design and KPI scorecards to motivate sales teams to fulfill business strategy plans. Debbie holds an MBA from University of Phoenix majoring in Business Administration and is a current Sharing Alliance Board Member.
Carlos G. Tessi has held medical, marketing and management positions in global pharma. He is credited with building and strengthening Merck & Co. Inc. worldwide Compliance infrastructure, developing its first global risk assessment methodology. With Merck acquisition of Schering Plough in 2009, he was instrumental in the integration of both compliance organizations worldwide. After retiring from Merck, he joined Bausch & Lomb as Global Pharmaceutical Compliance Director. When Bausch & Lomb was acquired by Valeant Pharmaceuticals, he joined Shionogi Inc. to lead the US Compliance office. Dr. Tessi was an active participant at the IFPMA’s Code Compliance Council, is a member of the Pharmaceutical Compliance Forum, and a regular speaker on Pharma Ethical Business Practices & Compliance topics.
Monique Thomas joined Supernus Pharmaceuticals in 2013. She has 9 years of experience in the Pharmaceutical Industry working with Medical Affairs, Operations, Sales Training and Sample Accountability. She is currently the Sample Accountability Supervisor managing sample distribution activities, legislative and compliance issues, as well as, training. Monique lives in Maryland with her husband Carlton and has 4 sons. She enjoys music, riding her motorcycle and volunteering in her community.
Scott Tinkel is Regional Business Director, Mid Atlantic Region, Hematology at Shire and has over 19 years of Sales, Marketing, Training/Development and Management experience in the biotech/pharmaceutical industry. As a leader of people with Johnson & Johnson and Shire, he has over 17 years as a second line and first line leader both in both Sales and Operations. In his role as a sales leader, his communication and collaboration skills have allowed him to work effectively with multiple stakeholders internally and externally, including Marketing, Medical, Legal, Compliance and Human Resources. On numerous occasions, Scott has delivered Compliance presentations to the field sales force and helped build out the pull through.
Joseph Tomkiewicz has spent over thirty years in the pharmaceutical industry, starting his career by mixing IV medications for hospice and nursing home patients. He spent ten years working in Regulatory Affairs for Bergen Brunswig and PharMerica, performing hundreds of operations, billing and DEA audits. Before taking his current position, he was the Diversion Control Program Manager for AmerisourceBergen, one of the largest wholesale distributors of pharmaceuticals in the US, and was responsible for the day-to-day operations of their suspicious order monitoring program. Currently he is a DEA Compliance Manager for Teva Pharmaceuticals, where he designed and is responsible for their Suspicious Order Monitoring Program.
Gregory Ungemach has been with MedPro Systems since 2012 focusing on designing, implementing, and supporting healthcare licensing solutions for the life science industry. Previously, Greg worked at Accenture, completing system integrations project for pharmaceutical manufacturers.
Robin Usi is Director, Division of Data & Informatics (DDI), Center for Program Integrity, Data Sharing & Partnership Group, Centers for Medicare & Medicaid Services (CMS). Robin will be presenting at the Sharing Conference this year with Amy Hammonds, Ian Mahoney and Veronika Peleshchuk Fradlin, Members of the CMS Open Payments Team.
Jennifer Valentine joined MedPro Systems in February of 2018, focusing on regulatory compliance and data quality to support healthcare provider and healthcare organization requirements for the life science industry. Prior to joining MedPro, Jennifer held similar roles over the past 20 years. Jennifer also served as a Sharing Alliance vendor board member.
Brian Van Hoy is an Ethics and Compliance Professional with extensive experience in the pharmaceutical and device industries. He has more than 30 years of experience within the healthcare industry across multiple functions and services. These areas include the establishment of an effective compliance program for new pharmaceutical and device companies and identifying opportunities to improve existing programs for established companies. In addition to compliance, Brian is experienced in sales, marketing, medical, regulatory and quality. Brian graduated from Purdue University having obtained a degree in Pharmacy. His current role is Vice President, G&M Health, LLC and previously as Director, Ethics and Compliance at Eli Lilly and Company.
Charles Washington is a subject matter expert on pharmaceutical diversion and product integrity. Charles has a fifteen year history addressing the diversion of pharmaceutical drugs purchased under discount pricing programs, and is an advocate for improving the 340B Program through good faith dispute resolutions. At Pfizer, Charles is the Director of an inter-departmental team from Global Compliance and Contract Strategy, and their role is to detect, investigate, and remediate the diversion of Pfizer drugs sold under discount pricing arrangements, which includes the 340B Discount Drug Program. He led the development of the company's current 340B Good-Faith Dispute Resolution Program, and has been successful in building cooperative relationships with 340B covered entities to address their 340B program violations and self-disclosures. Prior to joining Pfizer, Charles was a Special Agent with the Major Procurement Fraud Unit of the US Army Criminal Investigation Command.
Teresita Weiss Ph.D., J.D. is Sr. Vice President of Regulatory Affairs and Compliance for J. Knipper and Company, Inc., where she served under various management roles over the last 11 years including overseeing the Sample Accountability department, and now heads up the Quality Assurance, Regulatory Affairs and Compliance teams at Knipper. Teresita is a licensed attorney in the states of New Jersey and New York. Prior to joining Knipper, she served as defense counsel in matters involving pharmaceutical products liability. Teresita started her pharmaceutical career as a biochemist for Schering-Plough Research Institute.
Jeff Wilcox is Director of Sales Operations at Horizon Pharma. His role in pharma has included a variety of assignments in IT, Corporate Compliance and Sales Operations. Jeff is a current Member of the Sharing Alliance Board.